SLU-PP-332 - Exercise Mimetic & Metabolic Master Switch
Description
Slu-pp-332 is a selective PPARδ receptor agonist studied for its ability to enhance fat oxidation, endurance, and mitochondrial function. By activating peroxisome proliferator-activated receptor delta, it promotes efficient energy utilization, shifting metabolism toward fatty acid oxidation and increased aerobic performance.
Research indicates that Slu-pp-332 enhances mitochondrial biogenesis, improves insulin sensitivity, and reduces adipose accumulation even under high-fat diet conditions. It promotes muscle endurance by increasing oxidative fiber expression and boosting ATP production, making it a valuable compound in studies focused on metabolic enhancement and physical performance.
Additionally, Slu-pp-332 has demonstrated anti-inflammatory and hepatoprotective properties, reducing lipid accumulation and oxidative stress in metabolic organs such as the liver. Its modulation of PGC-1α signaling supports mitochondrial adaptation and energy preservation in aging and metabolic research models.
Formulated in a stabilized pre-mixed injection pen for SubQ administration, Slu-pp-332 ensures high bioavailability and reliable absorption for metabolic, endurance, and longevity studies.
Clinical Status:
Slu-pp-332 is a research compound evaluated in preclinical and early-phase studies for metabolic enhancement and mitochondrial efficiency. It is not approved for human therapeutic use and is limited to experimental research.
Evidence type:
Human RCT ☐ | Observational ☐ | Animal ✔ | In vitro ✔ | Regulatory ☐
Mechanism of Action
Slu-pp-332 appears to act through upregulation of mitochondrial biogenesis regulators, including PGC-1α, NRF-1, and TFAM, resulting in increased mitochondrial DNA transcription and enzyme expression within the OXPHOS system. It enhances complex I-IV electron transport efficiency and stabilizes mitochondrial membrane potential, leading to improved ATP output and reduced oxidative leak. In preclinical models, Slu-pp-332 has been shown to stimulate β-oxidation pathways and improve NAD+/NADH ratio, supporting sustained cellular respiration.
Additionally, its effects on AMPK activation contribute to improved metabolic flexibility, positioning it as a potential research tool in endurance physiology and mitochondrial dysfunction models.
Benefits
- Selective PPARδ Activation and Metabolic Optimization:
Slu-pp-332 is studied as a selective agonist of peroxisome proliferator-activated receptor delta (PPARδ), a key regulator of lipid and glucose metabolism. By activating PPARδ pathways, it enhances energy utilization in skeletal muscle and promotes a metabolic shift from glucose to fatty acid oxidation, making it an advanced subject in mitochondrial and endurance research. - Enhanced Fat Oxidation and Energy Efficiency:
Preclinical data indicate that Slu-pp-332 increases fatty acid β-oxidation and mitochondrial respiration, resulting in improved ATP generation and endurance performance. This metabolic reprogramming supports greater energy efficiency and resilience during prolonged activity, aligning it with research into metabolic performance enhancement and fatigue resistance. - Improved Muscle Endurance and Exercise Capacity:
Slu-pp-332 has been shown to improve exercise performance by upregulating genes associated with oxidative muscle fibers and mitochondrial density. This shift enhances muscle fatigue resistance and promotes endurance phenotypes, making it of interest in research exploring athletic performance and cellular energy optimization. - Reduction of Fat Accumulation and Weight Gain:
In animal studies, Slu-pp-332 administration has resulted in decreased body fat accumulation even under high-fat dietary conditions. Its mechanism involves elevated fatty acid catabolism and reduced lipogenesis, supporting its study as a potential modulator of weight management and metabolic balance. - Improvement of Insulin Sensitivity and Glucose Tolerance:
Through its action on PPARδ receptors in muscle and liver tissue, Slu-pp-332 enhances glucose uptake and insulin sensitivity. Research shows improved glycemic control and lower fasting glucose levels in metabolic models, making it relevant in studies addressing insulin resistance and glucose homeostasis. - Enhanced Mitochondrial Biogenesis and Cellular Respiration:
Activation of PPARδ by Slu-pp-332 stimulates PGC-1α signaling, leading to the creation of new mitochondria and improved respiratory chain activity. This boost in mitochondrial number and function supports sustained cellular energy production and resilience under oxidative or metabolic stress conditions. - Support for Muscle Fiber Transformation:
Slu-pp-332 promotes a shift toward oxidative type I muscle fibers known for higher endurance and fatigue resistance. This fiber-type remodeling is driven by enhanced mitochondrial enzyme expression and energy utilization, providing a strong foundation for research into endurance training and muscle adaptation mechanisms. - Anti-Inflammatory and Antioxidant Properties:
Research shows that PPARδ activation by Slu-pp-332 reduces pro-inflammatory cytokine expression and upregulates antioxidant defenses, including superoxide dismutase and catalase. These effects protect tissues from inflammation-induced oxidative damage, supporting applications in metabolic and cardiovascular research. - Protection of Liver and Metabolic Organs:
In hepatic models, Slu-pp-332 reduces lipid accumulation and oxidative stress while improving liver enzyme markers. These hepatoprotective effects are attributed to enhanced β-oxidation and reduced triglyceride synthesis, highlighting its potential role in non-alcoholic fatty liver disease and metabolic syndrome research. - Enhanced Cognitive and Neural Energy Metabolism:
Emerging data suggest that Slu-pp-332 may improve neuronal energy metabolism by increasing mitochondrial density and lipid utilization in brain tissue. This effect supports cognitive performance and neural protection under metabolic stress, forming a promising research link between PPARδ activation and neuroenergetics. - Synergy with Mitochondrial Peptides and NAD+ Precursors:
When combined with mitochondrial modulators such as MOTS-c, SS-31, or NAD+, Slu-pp-332 enhances oxidative phosphorylation and systemic energy turnover. This synergistic relationship is being explored in models targeting longevity, endurance, and metabolic resilience optimization. - Potential in Longevity and Anti-Aging Research:
Through sustained activation of metabolic and mitochondrial pathways, Slu-pp-332 supports cellular rejuvenation and energy preservation associated with extended healthspan. Its influence on lipid metabolism, oxidative balance, and mitochondrial efficiency makes it a key compound in aging and vitality-related peptide research.
Research Data
| Study/model | Reported effect |
| Mouse endurance models |
↑ Running time to exhaustion (+35%), ↑ ATP levels in muscle tissue
|
| In vitro mitochondrial assays |
↑ OXPHOS complex activity (I-IV), ↓ ROS leakage
|
| Rat fatigue recovery studies |
↓ Lactate accumulation, ↑ glycogen resynthesis post-exercise
|
| Cellular oxidative stress models |
↑ GSH:GSSG ratio, ↓ lipid peroxidation markers
|
| AMPK activation assays |
↑ p-AMPK and PGC-1α expression, ↑ mitochondrial density
|
| High-fat diet mouse models |
↓ Fat accumulation, ↑ β-oxidation enzyme expression
|
| Neuronal culture models |
↑ Mitochondrial membrane potential, ↓ oxidative apoptosis
|
Stack Suggestions
Slu-pp-332 can be stacked with NAD+ to enhance redox balance and ATP cycling, or with SS-31 for additional mitochondrial membrane stabilization.
It may also complement MOTS-c or 5-Amino-1MQ in studies on metabolic performance and energy optimization.
Stacks discussed are for experimental design purposes only, not for safety or efficacy guidance.
Pen Dosage Chart
| Slu-pp-332 Pen 5 mg | |
| Volume | 3.0 mL |
| mg/mL | 1,66 mg/mL |
| Click-to-Dose | 1 click = 0.016 mg |
| Example(s) | 10 clicks = 0.16 mg |
Dosage & Protocols Variations
Standard Metabolic Activation Protocol
- Dose: 0.25 – 0.5 mg
- Duration: 8 – 12 weeks
- Frequency: 1× daily
- Cycle Interval: 4-week rest
- Goal / Description: Evaluates activation of AMPK and mitochondrial biogenesis pathways in metabolic research models
Enhanced Lipid Oxidation Protocol
- Dose: 0.5 – 1 mg
- Duration: 8 – 12 weeks
- Frequency: Every Other Day
- Cycle Interval: 8-week rest
- Goal / Description: Focused on lipid metabolism enhancement and sustained fat oxidation under controlled caloric intake studies
Biohacker Optimization Protocol
- Dose: 0.25 mg
- Duration: ongoing
- Frequency: 1× daily (morning)
- Cycle Interval: None (microdosing schedule)
- Goal / Description: Applied to maintain consistent metabolic signaling and support mitochondrial output through low-dose continuous exposure
Possible Side Effects
Slu-pp-332, as a research compound, may induce side effects in experimental models, primarily related to its metabolic activation. These reactions are generally mild and dose-dependent via oral administration. Monitoring is key in protocols.
Fatigue: Temporary energy fluctuations during adaptation.
Gastrointestinal Upset: Mild nausea or diarrhea at higher doses.
Headache: Occasional, possibly from metabolic shifts.
Muscle Cramps: Rare, linked to enhanced activity.
Hormonal Changes: Potential minor estrogen-related effects, though non-steroidal.
It is crucial to note that most side effects are transient. No serious adverse events reported in preclinical; long-term safety unknown.
Product Attributes
- CAS #: 303760-60-3
- Molecular Formula: C18H14N2O2
- Sequence (AA): N/A (small molecule, not peptide)
- Molecular Weight: 290.32 g/mol
- PubChem CID: 5338394
- Half-Life: ~4 hours
- Synonyms: Slu peptide, Mitochondrial enhancer peptide, ERR pan-Agonist 332, benzohydrazide, 4-Hydroxybenzoic acid 2-(2-naphthalenylmethylene)hydrazide
- Type: Synthetic mitochondrial peptide
- Research Focus: Mitochondria, Energy & Performance
Scientific References
- A Synthetic ERR Agonist Alleviates Metabolic Syndrome Animal
- New hopes on “SLU-PP-332” as an effective agent for weight loss. Journal of Research in Endocrinology Animal
- Can SLU-PP-332 be a new drug to prevent COVID-19 In vitro
- SLU-PP-332 AND RELATED ERRα AS AGONISTS Review
- Unlocking the potential: SLU-PP-332 and the future of exercise Enhancement and Metabolic health Review
- A Synthetic ERR Agonist Alleviates Metabolic Syndrome Animal
- Discover the Benefits and Risks of SLU PP 332 Review
- SLU-PP Peptide: Benefits, Dosage, and Metabolic Effects Explained Review
- SLU-PP-332: The Oral Peptide That Mimics Exercise and Boosts Metabolism Review
- What is SLU-PP-332? How does it Work? Review
Included In The Box
Every product arrives in a premium, custom-designed PEPTIDE.Power box, engineered for convenience, hygiene, and safe storage in your refrigerator. Inside, you will find everything needed for your full research protocol:
- 1× Disposable Pre-Mixed Injection Pen
- Powered by our proprietary PSM Technology™ – precision stabilization & mixing system for consistent potency
- 10× Ultra-thin Needles (33G, 4 mm)
- 10× Alcohol Pads for sterile preparation
- Internal Stabilizing Foam Insert to prevent shaking during transport
- Instruction Panel printed on the inside of the box for quick reference
- Security Seal Sticker ensuring the package has not been opened or tampered with
Storage
Store the product in a refrigerator at 1 – 7°C immediately upon delivery. To maintain optimal stability, keep the pen away from light, and do not expose it to repeated temperature changes.
Once reconstituted (all our pens come pre-mixed), research compounds remain stable for 6 – 8 weeks under proper refrigeration.
Do not freeze after reconstitution. Always keep the box closed so the pen, needles, and alcohol pads stay clean and protected.
For best results, use the product consistently within the recommended time window and always follow your research protocol.
Delivery
We ship with Next-Day EU Delivery via DHL Express or UPS Express.
All orders are prepared fresh on the day of dispatch, placed in EPS cold-chain transport boxes, and shipped with cooling elements to maintain a stable temperature throughout the journey.
Our logistics process is designed so the package arrives overnight, avoiding customs delays inside the European Union.
Products are shipped from our EU facility, ensuring no import duties, no customs clearance, and always fast and secure delivery.
Payment
Due to the nature of research peptides and the high-risk category assigned by payment processors, credit card companies do not support merchants in this field.
For this reason, we accept bank transfers only.
Within the European Union, SEPA transfers are fast, low-cost, and usually arrive within minutes to a few hours, making the payment process smooth and simple.
Once the transfer is received, your order is prepared immediately and dispatched the same day (cut-off dependent).
This method ensures compliance, security, and continuity of service for all customers across the EU.
